Vabysmo vs Miebo
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Vabysmo | US Miebo | |
|---|---|---|
| Generic name | faricimab | perfluorohexyloctane |
| Drug class | VEGF/Ang-2 Bispecific Inhibitor (Eye Injection) | Semifluorinated Alkane (Eye Drop) |
| Treats | Wet macular degeneration, diabetic macular edema | Dry eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | Genentech (Roche) | Bausch + Lomb |
| Year approved | 2022 | 2023 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $85M | — |
| Common side effects | Eye inflammation, Floaters, Increased eye pressure, Blurred vision | Blurred vision, Eye redness, Temporary discomfort on application |
Frequently asked questions
Is Vabysmo or Miebo better?
Neither is universally "better." Vabysmo (faricimab) and Miebo (perfluorohexyloctane) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Vabysmo and Miebo?
Vabysmo is a VEGF/Ang-2 Bispecific Inhibitor (Eye Injection) made by Genentech (Roche), while Miebo is a Semifluorinated Alkane (Eye Drop) made by Bausch + Lomb. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Vabysmo has the larger estimated TV advertising budget of the two.